The Serum Institute of India (SII) which is a front-runner for providing coronavirus vaccine AZD1222 to India and other low and middle-income groups is because of a sub-licensing agreement with pharma major AstraZeneca. AstraZeneca along with the Oxford Vaccine group have developed AZD1222 one of the most promising coronavirus vaccine. In an email interview to Outlook’s Jyotika Sood, AstraZeneca’s vice president – medical affairs and regulatory Dr Anil Kukreja reveals the contours of the agreement. Excerpts: